INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against FibroGen, Inc and Encourages Investors with Losses of $100,000 to Contact the Firm

Published Apr 07 2021 at 8:44 PM GMT
  • The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc.
  • ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • FibroGen issued a statement on April 6, 2021, providing "clarification of certain prior disclosures of US primary cardiovascular safety analyses from the roxadustat Phase 3.


  • Published Apr 7, 2021 8:44 PM GMT